Literature DB >> 35367631

Improved biocompatibility of Zn-Ag-based stent materials by microstructure refinement.

Roger J Guillory1, Ehsan Mostaed2, Alexander A Oliver3, Lea M Morath4, Elisha J Earley4, Katie L Flom4, Timothy M Kolesar4, Ali Mostaed5, Henry D Summers2, Maria P Kwesiga4, Jaroslaw W Drelich2, Kent D Carlson6, Dan Dragomir-Daescu6, Jeremy Goldman7.   

Abstract

The metallurgical engineering of bioresorbable zinc (Zn)-based medical alloys would greatly benefit from clarification of the relationships between material properties and biological responses. Here we investigate the biocompatibility of three Zn-based silver (Ag)-containing alloys, ranging from binary to quinary alloy systems. Selected binary and quinary Zn-Ag-based alloys underwent solution treatment (ST) to increase the solubility of Ag-rich phases within the Zn bulk matrix, yielding two different microstructures (one without ST and a different one with ST) with the same elemental composition. This experimental design was intended to clarify the relationship between elemental profile/microstructure and biocompatibility for the Zn-Ag system. We found that the quinary alloy system (Zn-4Ag-0.8Cu-0.6Mn-0.15Zr) performed significantly better, in terms of histomorphometry, than any alloy system we have evaluated to date. Furthermore, when solution treated to increase strength and ductility and reduce the fraction of Ag-rich phases, the quinary alloy's biocompatibility further improved. In vitro corrosion testing and metallographic analysis of in vivo implants demonstrated a more uniform mode of corrosion for the solution treated alloy. We conclude that Zn-Ag alloys can be engineered through alloying to substantially reduce neointimal growth. The positive effect on neointimal growth can be further enhanced by dissolving the AgZn3 precipitates in the Zn matrix to improve the corrosion uniformity. These findings demonstrate that neointimal-forming cells can be regulated by elemental additions and microstructural changes in degradable Zn-based implant materials. STATEMENT OF SIGNIFICANCE: The metallurgical engineering of bioresorbable zinc (Zn)-based medical alloys would greatly benefit from clarification of the relationships between material properties and biological responses. Here, selected binary and quinary Zn-Ag-based alloys underwent solution treatment (ST) to increase the solubility of Ag-rich phases within the Zn bulk matrix, yielding two different microstructures (one without ST and a different one with ST) with the same elemental composition. We found that applying a thermal treatment restores mechanical strength and mitigates the strain rate sensitivity of Zn-Ag alloys by dissolving AgZn3 precipitates. Ag-rich nano-precipitates in Zn decrease biocompatibility, a phenomenon that can be counteracted by dissolving the AgZn3 precipitates in the bulk Zn matrix.
Copyright © 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alloys; Biodegradable; Metal; Silver; Stents; Zinc

Mesh:

Substances:

Year:  2022        PMID: 35367631      PMCID: PMC9189758          DOI: 10.1016/j.actbio.2022.03.047

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   10.633


  39 in total

1.  Corrosion behavior and biocompatibility evaluation of a novel zinc-based alloy stent in rabbit carotid artery model.

Authors:  Song Lin; Xiaolin Ran; Xinhao Yan; Wenhua Yan; Qilong Wang; Tieying Yin; Jack G Zhou; Tingzhang Hu; Guixue Wang
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2018-11-08       Impact factor: 3.368

2.  Copper stimulates proliferation of human endothelial cells under culture.

Authors:  G F Hu
Journal:  J Cell Biochem       Date:  1998-06-01       Impact factor: 4.429

3.  Analysis of vascular inflammation against bioresorbable Zn-Ag based alloys.

Authors:  Alexander A Oliver; Roger J Guillory; Katie L Flom; Lea M Morath; Timothy M Kolesar; Ehsan Mostaed; Malgorzata Sikora-Jasinska; Jaroslaw W Drelich; Jeremy Goldman
Journal:  ACS Appl Bio Mater       Date:  2020-09-24

4.  Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10.

Authors:  Nick D Tsihlis; Chris S Oustwani; Ashley K Vavra; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

Review 5.  Zinc-based alloys for degradable vascular stent applications.

Authors:  Ehsan Mostaed; Malgorzata Sikora-Jasinska; Jaroslaw W Drelich; Maurizio Vedani
Journal:  Acta Biomater       Date:  2018-03-10       Impact factor: 8.947

Review 6.  Challenges in the use of zinc and its alloys as biodegradable metals: Perspective from biomechanical compatibility.

Authors:  Guannan Li; Hongtao Yang; Yufeng Zheng; Xie-Hui Chen; Jian-An Yang; Donghui Zhu; Liqun Ruan; Kazuki Takashima
Journal:  Acta Biomater       Date:  2019-07-23       Impact factor: 8.947

Review 7.  Nitric oxide and superoxide in inflammation and immune regulation.

Authors:  T J Guzik; R Korbut; T Adamek-Guzik
Journal:  J Physiol Pharmacol       Date:  2003-12       Impact factor: 3.011

8.  Corrosion Characteristics Dictate the Long-Term Inflammatory Profile of Degradable Zinc Arterial Implants.

Authors:  Roger J Guillory; Patrick K Bowen; Sean P Hopkins; Emily R Shearier; Elisha J Earley; Amani A Gillette; Eli Aghion; Martin Bocks; Jaroslaw W Drelich; Jeremy Goldman
Journal:  ACS Biomater Sci Eng       Date:  2016-11-23

9.  Interfacial Zinc Phosphate is the Key to Controlling Biocompatibility of Metallic Zinc Implants.

Authors:  Yingchao Su; Hongtao Yang; Julia Gao; Yi-Xian Qin; Yufeng Zheng; Donghui Zhu
Journal:  Adv Sci (Weinh)       Date:  2019-05-17       Impact factor: 16.806

10.  Evaluation of a Zn-2Ag-1.8Au-0.2V Alloy for Absorbable Biocompatible Materials.

Authors:  Ping Li; Christine Schille; Ernst Schweizer; Evi Kimmerle-Müller; Frank Rupp; Xingting Han; Alexander Heiss; Andreas Richter; Claudia Legner; Ulrich E Klotz; Jürgen Geis-Gerstorfer; Lutz Scheideler
Journal:  Materials (Basel)       Date:  2019-12-20       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.